{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-032427","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2026-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.008605+00:00","generated_at":"2026-05-15T09:28:27.211466+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Milestone Pharma FY2025 net loss $63.1M; CARDAMYST launch on track; cash runway into late 2027","bullets":["Net loss of $63.1M ($0.75 per share) for FY2025 vs $41.5M ($0.67) prior year.","Revenue of $1.5M from CARDAMYST FDA approval milestone under Corxel agreement.","Commercial expense $28.3M for FY2025; 60-person sales force deployed mid-Feb.","Pro forma cash $200M including $75M RTW payment and $19M ATM/warrant exercises; runway to late 2027.","EMA accepted MAA for etripamil; decision expected H1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-032427","json":"https://secwatch.observer/filing/0001104659-26-032427.json","markdown":"https://secwatch.observer/filing/0001104659-26-032427.md","text":"https://secwatch.observer/filing/0001104659-26-032427.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926032427/0001104659-26-032427-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926032427/tm269403d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:28:27.211466+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"182d566eaa8dd5e5524fa17b73728a43a7f141c5","claim":"Milestone Pharmaceuticals Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2025.","evidence_excerpt":"On March 20, 2026, Milestone Pharmaceuticals Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926032427/0001104659-26-032427-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}